BioAlliance Pharma Presents the Results of an International Survey Performed with Nielsen in Patients Suffering from Herpes Labialis
PARIS--(BUSINESS WIRE)--Feb 7, 2011 - Regulatory News:
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, has presented the preliminary results of a study in patients suffering from herpes labialis in the United States and Europe. Given that treatment with Sitavir® (acyclovir Lauriad™) has proven efficacy in recurrent herpes labialis, the company considered it was important to better understand the characteristics of these patients affected by this recurrent disease.
Herpes labialis affects 50 million people in the US and 45 million in Europe each year. The study results included 2007 patients (1002 in the United States and 1005 in Europe-France) and are representative of epidemiological data on herpes labialis in terms of patient age, gender ratio and recurrence. In the United States, 74% of the patients were under the age of 49 (84% in France) and 59% were female (58% in France). Thirty-five percent of the study population presented 4 episodes and more a year (35% in France), with an annual average of 6 episodes.
Forty-six per cent of the US patients suffering from 4 episodes and more a year and with a medical prescription for herpes are welcoming a treatment that would treat herpes labialis and delay the occurrence of the following episode (38% in France).
Among the US patients with a medical prescription for herpes, 35% percent spontaneously stopped working on their own due to discomfort and significant inconvenience (17% in France) and among them, 66% had a sick leave prescription by a physician (59% in France).
Of the 1002 US patients, 44% had experienced an episode of herpes labialis in the 4 weeks preceding the study (47% in France). Use of a validated questionnaire revealed a significant alteration in quality of life of patients suffering from 4 episodes and more a year, relative to those suffering from fewer than 3 episodes a year (pain, physical disability and limited activities).
"These epidemiological results are very important for Sitavir® (acyclovir Lauriad™), indicated for recurrent herpes labialis and for which we intend to file marketing authorization in Europe and the US in Q3/Q4 2011. When recurrent, this local infection has an impact on quality of life. Patients with recurrent herpes labialis clearly have unmet medical needs", commented BioAlliance Pharma CEO, Dominique Costantini. "This study also tells us more about patients' treatment habits. It will yield valuable health economic data for the US and Europe and should also generate publications".
About BioAlliance Pharma
Dedicated to cancer and supportive care – cancer related
pathologies, chemotherapy and radiotherapy-induced complications
and opportunistic infections in immunocompromised patients –
BioAlliance conceives and develops innovative products, especially
in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in
2005, BioAlliance Pharma's ambition is to become a leading player
in these fields by coupling innovation to patient needs. The
company's teams have the key competencies required to identify,
develop and register drugs in Europe and the USA; the products'
commercialization rights are licensed to international commercial
partners invested in the hospital setting. In areas where medical
needs are insufficiently met, its targeted approaches help overcome
drug resistance and improve patient health & quality of
life.
BioAlliance Pharma has developed an advanced product
portfolio:
Loramyc®/Oravig® (oropharyngeal
candidiasis in immunocompromised patients): Registered in 26
European countries, in Korea and in the United States
Setofilm® (prevention and treatment of
-chemotherapy, radiotherapy and post operative- induced nausea and
vomiting in adults and children): Registered in 16 European
countries
Sitavir™ (Acyclovir Lauriad
TM) (labialis herpes): Positive phase
III final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive
preliminary Phase I results
AMEP® (invasive melanoma): Phase I
Clonidine LauriadTM (mucositis): Phase II
Doxorubicin Transdrug® (liver cancer): Phase
II
For more information, visit the BioAlliance Pharma web site
at
www.bioalliancepharma.com
About The Nielsen Company
The survey was performed with an appropriate methodology and a
validated questionnaire by the Nielsen Company, the global
information and measurement company with leading market positions
in marketing and consumer information.
The Nielsen Company is an international company specialized in the medical and pharmaceutical areas and its Consumer Research department is expert in ad hoc consumer studies, especially in Online Multi-Countries studies. More generally, the Nielsen is a global information and measurement company with leading market positions in marketing and consumer information, television and other media measurement, online intelligence, mobile measurement, trade shows and related assets. The company has a presence in approximately 100 countries, with headquarters in New York, USA. For more information on The Nielsen Company, visit www.nielsen.com.
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of
BioAlliance Pharma SA to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. BioAlliance Pharma SA is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.
For a discussion of risks and uncertainties which could cause
actual results, financial condition, performance or achievements of
BioAlliance Pharma SA to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the 2009 Reference Document filed
with the AMF on June 29, 2010, which is available on the AMF
website (http://www.amf-france.org)
or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
Contact: BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
or
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com
or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com
or
Laurence Delval
Tel : + 33 1 42 68 86 42
Laurence@alizerep.com
Posted: February 2011
